
Eli Lilly and Company LLY
$ 987.05
-0.19%
Annual report 2025
added 02-12-2026
Eli Lilly and Company ROA Ratio 2011-2026 | LLY
Annual ROA Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.35 | 13.45 | 8.19 | 12.62 | 11.44 | 13.28 | 21.17 | 7.36 | -0.45 | 7.05 | 6.77 | 6.43 | 13.29 | 11.89 | 12.92 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.17 | -0.45 | 10.92 |
Quarterly ROA Ratio Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.11 | 12.01 | 8.82 | 10.75 | 9.15 | 8.71 | 11.86 | 12.7 | 11.17 | 13.47 | 8.66 | 11.57 | 8.11 | 10.7 | 10.98 | 11.1 | 8.74 | 12.55 | 13.15 | 13.5 | 21.17 | 19.93 | 19.36 | 15.39 | 7.36 | 1.12 | -0.27 | 2.57 | -0.45 | 5.22 | 5.99 | 5.67 | 7.05 | 6.41 | 6.65 | 6.42 | 6.77 | 6.61 | 5.71 | 5.99 | 6.46 | 7.34 | 9.41 | 10.86 | 13.29 | 13.63 | 14.07 | 13.34 | 11.89 | 13.15 | 12.97 | 13.84 | 10.37 | 3.67 | 3.56 | 3.14 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.17 | -0.45 | 9.6 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
65.02 | - | - | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | ||
|
INmune Bio
INMB
|
-141.98 | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Exelixis
EXEL
|
27.51 | $ 48.7 | 9.64 % | $ 13.2 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 21.48 | -3.89 % | $ 3.56 B | ||
|
Fortress Biotech
FBIO
|
3.67 | - | - | $ 71.1 M | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.15 | 1.19 % | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | - | - | $ 5.51 M | ||
|
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.17 | 3.2 % | $ 3.08 B | ||
|
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-206.68 | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 55.08 | 5.15 % | $ 4.95 B | ||
|
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.7 | 3.66 % | $ 452 M | ||
|
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
2.66 | - | - | - | ||
|
Фармсинтез
LIFE
|
-25.57 | - | - | - | ||
|
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | ||
|
Galapagos NV
GLPG
|
-1.99 | $ 28.81 | 1.48 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
22.5 | $ 27.89 | 1.34 % | $ 17.2 B |